MedTrace Logo

Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections

NCT00108433 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2012-08-07

Study results available
· View outcomes & findings →

Summary

This study will treat hemodialysis patients who have a central catheter that is thought to be infected with a specific bacteria (Gram positive bacteria).

Conditions

  • Bacteremia
  • Gram-Positive Bacterial Infections

Interventions

DRUG

Cefazolin IV

DRUG

Linezolid IV

DRUG

Vancomycin (IV)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2006-09-30

Countries

  • United States
  • Colombia
  • India
  • Israel
  • Italy
  • Poland
  • Slovakia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00108433 on ClinicalTrials.gov